Corporate and Regional Press Releases

Please find below a list of our press releases.

11 Jun 2018

ELEVATE study aims to improve selection criteria and outcomes for patients with severe emphysema treated with the PneumRx Endobronchial Coil System

BTG plc (LSE: BTG), the global healthcare company, today announces the start of ELEVATE: A randomizEd ControlLed Study of PnEumRx™ Endobronchial Coil System (Coils) Versus Standard of Care Medical MAnagement in the Treatment of Subjects with Severe Emphysema.

27 Apr 2018

OPTALYSE PE Results Presented at Society for Cardiovascular Angiography and Interventions

BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California. The findings further confirm that bilateral pulmonary embolism treated in as little as 2 hours with significantly less tissue plasminogen activator (tPA) than used in previous studies1- as low as 8mg total - show significant improvement in RV/LV ratio over both the short and long term and with a very low mortality rate of 2% and an equally low recurrent PE rate of 2%.

4 Apr 2018

SIO and BTG Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program

The Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, and BTG plc (LSE: BTG), a global healthcare company focused on Interventional Medicine, announce their 2018 Interventional Oncology/Immuno-Oncology research grant recipients.

21 Feb 2018

First Patient in Latin America Receives TheraSphere® Radioembolisation Treatment

February 28, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, announced the first patient in Latin America in Mexico was treated with TheraSphere® – a treatment for hepatic neoplasia that delivers powerful radiation to tumour cells and minimizes the exposure to healthy tissue.

6 Feb 2018

OPTALYSE PE Long Term Results Reinforce Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

BTG plc (LSE: BTG), the global healthcare company, today highlighted OPTALYSE PE one year trial results, presented at the International Society on Endovascular Therapy in Florida.

13 Dec 2017

Centers Commence Enrollment in KNOCOUT PE Study to Measure the Impact of Shorter, Even Safer EKOS® Therapy Protocols for Pulmonary Embolism

BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how hospitals and patients are benefitting from a new standard of care in the treatment of Pulmonary Embolism utilizing EKOS® therapy with faster, and even safer protocols, proven effective in the OPTALYSE PE study.

11 Dec 2017

Institutional Decision to Adopt Y90 TARE with TheraSphere® as first-line treatment for HCC

Based on experience with 1000 patients over 15 years, the largest single-centre, prospective centre cohort of patients with HCC treated with Y90 glass microspheres

9 Oct 2017

First patient treated with microscopic beads pre-loaded with a targeted cancer drug and visible on CT scans

Researchers from the UCL Cancer Institute and the specialist healthcare company BTG plc (LSE: BTG) have begun the first clinical trial of an experimental treatment for liver cancer using X-ray imageable microscopic beads loaded with a targeted anti-cancer drug placed directly in the liver.

5 Oct 2017

BTGplc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

27 Sep 2017

Mirada Medical signs three-year software development agreement with BTG

Mirada Medical Ltd, a global medical imaging software company, has signed a three-year master service agreement with BTG plc (LSE: BTG), a global specialist healthcare company. The agreement covers multiple software development projects to support BTG’s portfolio of interventional medicine products.